Velpanex 400 mg & 100 mg (Sofosbuvir & Velpatasvir)


Velpanex 400 mg & 100 mg (Sofosbuvir & Velpatasvir)

Introduction to Velpanex 400 mg & 100 mg (Sofosbuvir & Velpatasvir)

Velpanex 400 mg & 100 mg, expertly developed by Everest Pharmaceuticals Ltd. and supplied by Orio Pharma, represents a groundbreaking solution in the treatment of chronic hepatitis C. The combination of Sofosbuvir and Velpatasvir offers a comprehensive, once-daily regimen that targets all major genotypes of the hepatitis C virus (HCV).

Description: Velpanex 400 mg & 100 mg (Sofosbuvir & Velpatasvir)

Velpanex combines two potent antiviral agents:

  • Sofosbuvir (400 mg): A nucleotide analog NS5B polymerase inhibitor.
  • Velpatasvir (100 mg): An NS5A inhibitor.

This combination works synergistically to disrupt the lifecycle of the HCV, providing a high cure rate for patients with chronic hepatitis C.

Mechanism of Action

  • Sofosbuvir: Inhibits the NS5B RNA-dependent RNA polymerase, essential for viral replication.
  • Velpatasvir: Inhibits the NS5A protein, critical for viral RNA replication and virion assembly.

Together, these agents prevent the virus from multiplying and spreading, leading to the clearance of the virus from the bloodstream.

Clinical Use

Velpanex 400 mg & 100 mg is primarily prescribed for:

  • Chronic Hepatitis C Treatment: Effective against all six major HCV genotypes, including patients with or without cirrhosis and those who have failed previous treatments.

Dosage and Administration

Healthcare professionals determine the dosage of Velpanex based on individual patient profiles. The standard regimen involves taking one tablet (400 mg Sofosbuvir and 100 mg Velpatasvir) orally once daily, with or without food, for a duration typically lasting 12 weeks.

Benefits of Velpanex 400 mg & 100 mg (Sofosbuvir & Velpatasvir)

  • Pan-genotypic Efficacy: Effective against all major HCV genotypes.
  • High Cure Rates: Achieves sustained virologic response (SVR) in the majority of patients.
  • Convenient Dosing: Once-daily oral tablet simplifies treatment adherence.
  • Well-Tolerated: Minimal side effects compared to other HCV treatments.

Manufacturer: Everest Pharmaceuticals Ltd.

Everest Pharmaceuticals Ltd., the esteemed manufacturer of Velpanex, is committed to producing high-quality medications. Their rigorous quality control and innovative approaches ensure Velpanex meets the highest standards of efficacy and safety.

Supplier: Orio Pharma

Orio Pharma, the trusted supplier of Velpanex, ensures that this crucial medication is accessible to healthcare providers and patients globally. Their dedication to excellence in distribution guarantees timely and reliable access to Velpanex.


In conclusion, Velpanex 400 mg & 100 mg (Sofosbuvir & Velpatasvir) is a revolutionary treatment for chronic hepatitis C. Manufactured by Everest Pharmaceuticals Ltd. and supplied by Orio Pharma, this combination therapy offers a potent and convenient solution for patients battling HCV.

The dual-action mechanism of Sofosbuvir and Velpatasvir underscores its effectiveness as a therapeutic option. The collaboration between Everest Pharmaceuticals Ltd. and Orio Pharma ensures the highest standards of manufacturing and distribution, making Velpanex a reliable and accessible choice for achieving sustained virologic response and improved health outcomes in chronic hepatitis C patients.